] . (1998). Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. J Infec Dis, 177, 310-319. presented at the 02/1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466516
. (1998). Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infec Dis, 177, 1230-46. presented at the 1998.
. (1999). A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infec Dis, 180, 290-8. presented at the 1999.
. (1999). HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. AIDS Res HumRetroviruses, 15, 115-32. presented at the 1999.
. (1999). Immunization with envelope MN rap 120 vaccine in human immunodeficiency virus infected pregnant women. J Infec Dis, 180, 1080-8. presented at the 1999.
. (2001). Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infec Dis, 183, 1343-52. presented at the 2001.